Bio-Techne (TECH) Notes Payables (2014 - 2022)
Bio-Techne (TECH) posted quarterly Notes Payables of $500000.0 for Q2 2022, down 37.5% year-over-year from $800000.0 in Q2 2021, and down 75.0% quarter-over-quarter from $2.0 million in Q1 2022.
Powered by 
Analysis
Bio-Techne (TECH) Notes Payables (2014 - 2022) Analysis & Trends
Bio-Techne's Notes Payables history runs 6 years deep, the most recent figure standing at $500000.0 for Q2 2022.
- In Q2 2022, Notes Payables fell 37.5% year-over-year to $500000.0; the TTM figure through Jun 2022 stood at $500000.0 (down 37.5% YoY), while the FY2022 annual figure was $500000.0, down 37.5% from the prior year.
- Notes Payables for Q2 2022 stood at $500000.0, down from $2.0 million in the prior quarter.
- The five-year high for Notes Payables was $2.0 million in Q1 2022, with the low at $200000.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 2.00 Mn |
| Sep 30, 2021 | 200,000.00 |
| Jun 30, 2021 | 800,000.00 |
| Mar 31, 2017 | 14.58 Mn |
| Dec 31, 2016 | 3.60 Mn |
| Sep 30, 2016 | 3.73 Mn |
| Jun 30, 2016 | 3.76 Mn |
| Mar 31, 2016 | 3.81 Mn |
| Dec 31, 2015 | 3.79 Mn |
| Sep 30, 2015 | 3.87 Mn |
| Jun 30, 2015 | 4.02 Mn |
| Mar 31, 2015 | 3.00 Mn |
| Dec 31, 2014 | 5.98 Mn |
| Sep 30, 2014 | 5.95 Mn |
| Jun 30, 2014 | 5.95 Mn |